Clinical Pharmacology and Therapeutics

Publication Venue For
- A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).. 105:738-745. 2019
- A Novel Method to Estimate Long-Term Chronological Changes From Fragmented Observations in Disease Progression.. 105:436-447. 2019
- Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia. 2018
- Pharmacologic Targeting of Red Blood Cells to Improve Tissue Oxygenation.. 104:553-563. 2018
- Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.. 103:778-786. 2018
- Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia.. 103:888-898. 2018
- Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality.. 103:202-205. 2018
- Emerging Therapies for Congestive Heart Failure.. 103:77-87. 2018
- Cancer Moonshot Data and Technology Team: Enabling a National Learning Healthcare System for Cancer to Unleash the Power of Data.. 101:613-615. 2017
- Improving the tools of clinical pharmacology: Goals for 2017 and beyond.. 101:22-24. 2017
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.. 99:36-37. 2016
- Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.. 98:71-75. 2015
- Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection.. 98:25-33. 2015
- Improving evidence developed from population-level experience with targeted agents.. 97:478-487. 2015
- Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase.. 97:326-335. 2015
- GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety. 96:704-712. 2014
- Career Profile. 96:411-411. 2014
- Phenotype standardization for statin-induced myotoxicity. 96:470-476. 2014
- Phenotype standardization for statin-induced myotoxicity.. 96:470-476. 2014
- The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. 96:423-428. 2014
- The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.. 96:423-428. 2014
- Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents.. 96:429-437. 2014
- Improving the assessment of heart toxicity for all new drugs through translational regulatory science.. 95:501-508. 2014
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-Based Regimens. 95:141-146. 2014
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.. 95:141-146. 2014
- Integrated efficacy to effectiveness trials.. 95:131-133. 2014
- Pharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology. 95:154-167. 2014
- Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.. 95:154-167. 2014
- Biomarkers for smoking cessation.. 93:526-538. 2013
- A Network-Heuristic Approach to Improve the Impact of Genomic Data on Drug Discovery. 93:295-297. 2013
- Drug shortages in the United States: a critical evaluation of root causes and the need for action.. 93:133-135. 2013
- Using genetics to enable studies on the prevention of Alzheimer's disease.. 93:177-185. 2013
- Biomarkers for smoking cessation. 93:526-538. 2013
- Integration of Pharmacometabolomic and Pharmacogenomic Approaches Reveals Novel Insights Into Antiplatelet Therapy 2013
- Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. 94:570-573. 2013
- Pharmacometabolomics of Statin Response 2013
- Pharmacometabolomics of statin response. 94:562-565. 2013
- Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed Pharmacogenomics 2013
- Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics. 94:525-532. 2013
- The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure.. 93:57-67. 2013
- The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.. 92:112-117. 2012
- Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine.. 91:889-895. 2012
- Impediments to clinical research in the United States.. 91:535-541. 2012
- Rational opioid dosing in the elderly: dose and dosing interval when initiating opioid therapy.. 91:339-343. 2012
- Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study.. 90:860-866. 2011
- Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.. 90:568-574. 2011
- The Achilles' heel of cardiovascular genetic testing: distinguishing pathogenic mutations from background genetic noise.. 90:496-499. 2011
- Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.. 90:25-27. 2011
- Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.. 89:702-707. 2011
- Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.. 89:97-104. 2011
- Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection.. 88:708-711. 2010
- Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials.. 87:668-671. 2010
- The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.. 87:539-542. 2010
- A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.. 87:445-451. 2010
- Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy.. 87:226-234. 2010
- Safety and pharmacokinetics of repeat-dose micafungin in young infants.. 87:93-99. 2010
- Clinical trial design in neonatal pharmacology: effect of center differences, with lessons from the Pediatric Oncology Cooperative Research experience.. 86:589-591. 2009
- QT as a safety biomarker in drug development.. 86:101-104. 2009
- Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.. 85:394-401. 2009
- Erratum: Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: A meta-analysis (Clinical Pharmacology Therapeutics (2008) 84, (315-319)). 84:636. 2008
- Racial Differences in Blood Pressure Response toAngiotensin-Converting Enzyme Inhibitors in Children: A Meta-Analysis (vol 84, pg 315, 2008). 84:636-636. 2008
- The Reference Image Database to Evaluate Response to therapy in lung cancer (RIDER) project: a resource for the development of change-analysis software.. 84:448-456. 2008
- Corrigendum: Editorial (Clinical Pharmacology Therapeutics (2008) 84, (3-6) DOI: 10.1038/clpt.2008.99). 84:430. 2008
- Corrigendum: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin (Clinical Pharmacology Therapeutics (2008) 84, (326-331) DOI: 10.1038/clpt.2008.10). 84:430. 2008
- Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis.. 84:315-319. 2008
- Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.. 84:326-331. 2008
- Anesthesia: a discipline that incorporates clinical pharmacology across the DDRU continuum.. 84:3-6. 2008
- Inhaled anesthesia: the original closed-loop drug administration paradigm.. 84:15-18. 2008
- Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.. 84:83-89. 2008
- Processed EEG (bispectral index) is not appropriate for characterizing opioid sedation.. 83:667-668. 2008
- Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response. 83:160-166. 2008
- The importance of including swine and poultry workers in influenza vaccination programs. 82:638-641. 2007
- The importance of including swine and poultry workers in influenza vaccination programs.. 82:638-641. 2007
- Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.. 82:601-605. 2007
- Should the patent system for new medicines be abolished?. 82:488-490. 2007
- Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics.. 82:118-121. 2007
- Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships.. 74:569-580. 2003
- Regulating manufacturer-affiliated communication in the information age.. 65:593-597. 1999
- Stereoselective monitoring of ± verapamil treatment of women with bipolar disorder. 65:158. 1999
- Benzodiazepine use and cognitive function among community-dwelling elderly.. 64:684-692. 1998
- Eptifibatide pharmacokinetics in patients undergoing coronary angioplasty.. 63:232-232. 1998
- Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. 61:205. 1997
- Bidirectional interaction of valproate and lamotrigine in healthy subjects.. 60:145-156. 1996
- Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor. 59:PI84-PI84. 1996
- Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone.. 56:86-99. 1994
- Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers.. 54:670-679. 1993
- Treatment of paroxysmal supraventricular tachycardia with oral diltiazem.. 51:562-565. 1992
- Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics.. 51:371-378. 1992
- Differential response of beta-adrenergic receptor-mediated heart rate and aortic blood flow acceleration to timolol.. 51:296-301. 1992
- PHARMACOKINETICS (PK) OF L-OFLOXACIN IN HIV-INFECTED PATIENTS. 51:182-182. 1992
- Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol.. 51:18-23. 1992
- New drug application strategies for supraventricular arrhythmias.. 49:481-487. 1991
- A COMPARISON OF PAIN, SEDATION, AND RESPIRATORY DEPRESSION FOLLOWING PENTAMORPHONE OR FENTANYL GENERAL-ANESTHESIA. 49:182-182. 1991
- Pharmacodynamics of propranolol on left ventricular function: assessment by Doppler echocardiography.. 48:431-438. 1990
- Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril.. 48:447-454. 1990
- Benefits, risks, and costs of prescription drugs: a scientific basis for evaluating policy options.. 48:111-119. 1990
- Transdermal nicotine facilitates smoking cessation.. 47:323-330. 1990
- NICARDIPINE VS SODIUM-NITROPRUSSIDE FOR TREATMENT OF POSTOPERATIVE HYPERTENSION. 47:198-198. 1990
- Comparison between continuous and intermittent infusion regimens of cimetidine in ulcer patients.. 46:234-239. 1989
- Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension.. 46:208-218. 1989
- Erratum: Comparison between continuous and intermittent infusion regimens of cimetidine in ulcer patients (Clin Pharmacol Ther 1989; 46: 234-9). 46:500. 1989
- Oral dipyridamole increases plasma adenosine levels in human beings.. 45:80-84. 1989
- Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin.. 44:78-92. 1988
- Short-term behavioral effects of beta-adrenergic medications in men with mild hypertension.. 43:429-435. 1988
- Chronic effects of nitrendipine on renal hemodynamics and tubular transport.. 43:6-15. 1988
- Short-term behavioral effects of beta-adrenergic medications in men with mild hypertension. 43:429-435. 1988
- Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations. 39:25-28. 1986
- Transdermal nicotine reduces cigarette craving and nicotine preference. 38:450-456. 1985
- Tocainide kinetics in congestive heart failure.. 34:596-603. 1983
- Hemodynamic effects of the antiarrhythmic drug pirmenol. 32:235-239. 1982
- Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction.. 30:154-157. 1981
- Clonidine-chlorthalidone combination once and twice daily in essential hypertension.. 28:581-586. 1980
- Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney.. 28:680-689. 1980
- Nonemergency use of slow infusions of diazoxide.. 18:154-157. 1975
- Monoamine precursors in the treatment of depression.. 12:743-761. 1971
- Laboratory and clinical studies of penicillin X-1497.. 2:70-79. 1961
- METABOLOMIC SIGNATURE OF EXPOSURE AND RESPONSE TO CITALOPRAM/ESCITALOPRAM IN CLINICAL SUBTYPES OF MAJOR DEPRESSION: METABOLOMICS INFORMS ABOUT DISEASE HETEROGENEITY. 2019
- METABOLOMIC SIGNATURE OF EXPOSURE AND RESPONSE TO CITALOPRAM/ESCITALOPRAM IN CLINICAL SUBTYPES OF MAJOR DEPRESSION: METABOLOMICS INFORMS ABOUT DISEASE HETEROGENEITY. 2019
- METABOLOMIC SIGNATURES OF DRUG RESPONSE PHENOTYPES FOR CITALOPRAM AND ESCITALOPRAM IN SUBJECTS WITH MAJOR DEPRESSIVE DISORDER. 2019
- METABOLOMIC SIGNATURES OF DRUG RESPONSE PHENOTYPES FOR CITALOPRAM AND ESCITALOPRAM IN SUBJECTS WITH MAJOR DEPRESSIVE DISORDER. 2019
- SEX-SPECIFIC DIFFERENCES IN THE METABOLOME IN RESPONSE TO CITALOPRAM/ ESCITALOPRAM EXPOSURE. 2019
- SEX-SPECIFIC DIFFERENCES IN THE METABOLOME IN RESPONSE TO CITALOPRAM/ ESCITALOPRAM EXPOSURE. 2019
- DOSE-RELATED INFLAMMATORY EFFECTS OF INTRAVENOUS ENDOTOXIN IN HUMANS: EVALUATION OF A NEW CLINICAL LOT (CCRE LOT 94332B1) OF ESCHERICHIA COLIO: 113 ENDOTOXIN (LPS). 2018
- PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF FLUCONAZOLE USING PLASMA AND CEREBROSPINAL FLUID SAMPLES COLLECTED FROM PRETERM AND TERM INFANTS. 2018
- INTRA-TARGET MICRODOSING (ITM), A NOVEL DRUG DEVELOPMENT APPROACH: PROOF-OF-CONCEPT IN HUMANS 2017
- LEAN BODY WEIGHT (LBW) DOSING OF PANTOPRAZOLE IS APPROPRIATE FOR OBESE CHILDREN. 2017
- A METFORMIN METABOLOMIC EXPRESSION PROFILE STUDY UTILIZING AN ELECTRONIC HEALTH RECORD (EHR)-LINKED BIOREPOSITORY AND INTEGRATIVE MOLECULAR EPIDEMIOLOGY APPROACHES 2016
- ANTIFUNGAL EXTRACTION BY THE EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) CIRCUIT EX VIVO. 2015
- VATALANIB POPULATION PHARMACOKINETICS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: CALGB 10105 (ALLIANCE) 2013
- GLYCINE AND A GLYCINE DEHYDROGENASE (GLDC) SNP AS SSRI RESPONSE BIOMARKERS IN DEPRESSION: PHARMACOMETABOLOMICS-INFORMED PHARMACOGENOMICS 2011
- GLYCINE AND A GLYCINE DEHYDROGENASE (GLDC) SNP AS SSRI RESPONSE BIOMARKERS IN DEPRESSION: PHARMACOMETABOLOMICS-INFORMED PHARMACOGENOMICS 2011
- DIFFERING SIROLIMUS-INDUCED HYPERLIPIDEMIA AND RESPONSE TO STATIN THERAPY BETWEEN CYP3A5 EXPRESSERS AND NON-EXPRESSERS IN KIDNEY TRANSPLANTATION. 2009
- USE OF MONTE CARLO SIMULATION (MCS) TO EVALUATE TOXICITY AND EFFICACY BREAKPOINTS OF A NOVEL ANTIBIOTIC 2009

Publication Venue For